"Pragmatic" clinical trials: from whose perspective? (Editorial)

Karanicolas, Paul J.; Montori, Victor M.; Schünemann, Holger J.; Guyatt, Gordon H.
June 2009
ACP Journal Club;6/23/2009, Vol. 150 Issue 6, p1
Academic Journal
The article reflects on pragmatic clinical trials carried out by methodologists in the field of medical research. It argues that the current concept of pragmatic trials only serves a small proportion of health care decision makers. It offers an interpretation of a self-described pragmatic trial of the drug nortriptyline as an adjunct to nicotine replacement for smoking cessation. It discusses the trial under three perspectives and their inherent results.


Related Articles

  • BUPROPION FOR SMOKING CESSATION. Jackson, Eric A. // Journal of Family Practice;Feb1998, Vol. 46 Issue 2, p111 

    The article discusses research being done on the use of bupropion and placebo for smoking cessation, with reference to a study by R. D. Hurt, D. P. L. Sachs, E. D. Glover et al, which appeared in the 1997 issue of the "New England Journal of Medicine." The randomized, double-blind study...

  • Evotec's MAO-B Inhibitor Fails in Phase II Trial.  // Bioworld Week;4/20/2009, Vol. 17 Issue 16, p4 

    The article reports on the result of the Phase II clinical trial of smoking cessation drug called EVT 302 that failed to show improvement in the quit rate of smokers, and reassesses the manufacturer Evotec AG plans to reassess the drug following further analysis. EVT 302, a monoamine oxidase B...

  • Therapeutic Drug Monitoring of Nortriptyline in Smoking Cessation: A Multistudy Analysis. Mooney, M. E.; Reus, V. I.; Gorecki, J.; Hall, S. M.; Humfleet, G. L.; Muñoz, R. F.; Delucchi, K. // Clinical Pharmacology & Therapeutics;Mar2008, Vol. 83 Issue 3, p436 

    Multiple, controlled clinical trials support the efficacy of nortriptyline as a smoking cessation agent. Although therapeutic plasma nortriptyline concentrations (PNCs) are known for the treatment of depression, little is known about PNCs in smoking cessation treatment. PNCs from three...

  • Do small lapses predict relapse to smoking behavior under bupropion treatment? Wileyto, E. Paul; Patterson, Freda; Niaura, Raymond; Epstein, Leonard H.; Brown, Richard A.; Audrain-mcgovern, Janet; Hawk Jr., Larry W.; Lerman, Caryn; Wileyto, Paul; Epstein, Leonard; Brown, Richard; Hawk, Larry // Nicotine & Tobacco Research;Apr2004, Vol. 6 Issue 2, p357 

    Although bupropion is known to be an effective aid to smoking cessation, little is known about its mode of action. In the present study we tested the hypothesis that bupropion reduces the likelihood that a smoking lapse, or slip, leads to a subsequent relapse. This hypothesis was tested in the...

  • Achieving high rates of consent for genetic testing among African American smokers. Cox, Lisa Sanderson; Bronars, Carrie A.; Thomas, Janet L.; Okuyemi, Kolawole S.; King, Gary; Mayo, Matthew S.; Ahluwalia, Jasjit S. // Nicotine & Tobacco Research;Jun2007, Vol. 9 Issue 6, p711 

    Genetic factors play an important role in smoking behavior. Although African Americans are at disproportionately increased risk for tobacco-related morbidity and mortality, limited attention has been given to genetic investigation of tobacco use in this population. The present study examined...

  • Well informed uncertainties about the effects of treatments. Chalmers, Iain // BMJ: British Medical Journal (International Edition);2/28/2004, Vol. 328 Issue 7438, p475 

    Discusses uncertainties about the effects of medical treatments. Decision-making and treatment options; Clinician-patient relationship; Clinical trials; Approaches to dealing with uncertainty; Contention that strategies for dealing with uncertainty need to be debated more explicitly;...

  • "Hello, hello--it's English I speak!": a qualitative exploration of patients' understanding of the science of clinical trials. Stead, M.; Eadie, D.; Gordon, D.; Angus, K. // Journal of Medical Ethics;Nov2005, Vol. 31 Issue 11, p664 

    Informed consent may be seriously compromised if patients fail to understand the experimental nature of the trial in which they are participating. Using focus groups, the authors explored how prospective trial participants interpret and understand the science of clinical trials by using patient...

  • Heterogeneity prevails: the state of clinical trial data management in Europe--results of a survey of ECRIN centres. Kuchinke, Wolfgang; Ohmann, Christian; Qin Yang; Salas, Nader; Lauritsen, Jens; Gueyffier, Francois; Leizorovicz, Alan; Schade-Brittinger, Carmen; Wittenberg, Michael; Voko, Zoltán; Gaynor, Siobhan; Cooney, Margaret; Doran, Peter; Maggioni, Aldo; Lorimer, Andrea; Torres, Ferràn; McPherson, Gladys; Charwill, Jim; Hellström, Mats; Lejeune, Stéphane // Trials;2010, Vol. 11, p79 

    Background: The use of Clinical Data Management Systems (CDMS) has become essential in clinical trials to handle the increasing amount of data that must be collected and analyzed. With a CDMS trial data are captured at investigator sites with "electronic Case Report Forms". Although more and...

  • Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010. Califf, Robert M.; Zarin, Deborah A.; Kramer, Judith M.; Sherman, Rachel E.; Aberle, Laura H.; Tasneem, Asba // JAMA: Journal of the American Medical Association;5/2/2012, Vol. 307 Issue 17, p1838 

    The article examines the basic characteristics of interventional clinical trials in cardiovascular, mental health and oncology therapeutic areas contained in the ClinicalTrials.gov database of the U.S. The discrepancies between guidelines-based treatment recommendations and evidence from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics